Introduction
Lung cancer is the leading cause of cancer-related death in the world (1) . Lung cancer was the leading indication for respiratory surgery (42.2%) in 1998 in Japan (2) . More than 15000 patients underwent surgical operation at Japanese institutions in 1998 (2) . Despite the advances made in surgery, chemotherapy, and radiotherapy, the overall 5-year survival rate still remains at 15%. Other therapeutic targets and agents are needed for the management of non-small cell lung cancer (NSCLC).
Overexpression of the epidermal growth factor receptor (EGFR) in multiple human tumors has been extensively documented and alterations within the EGFR gene may be as important as overexpression for oncogenic effect (3, 4) . EGFR is abundantly expressed in NSCLC (5, 6) . EGFR tyrosine kinase inhibitor, gefitinib, was approved in Japan for the treatment of NSCLC from 2002. We have found that EGFR mutation status at kinase domain in Japanese NSCLC patients was correlated with the clinicopathological features related to good response to gefitinib (7) (8) (9) (10) . EGFR mutations in lung cancer have been correlated with clinical response to gefitinib therapy in vivo and in vitro (7, 11, 12) . More recently, another EGFR inhibitor cetuximab was approved for treatment of colon cancer. It has been reported that EGFR gene amplification is correlated with clinical response to cetuximab therapy (13) . Clinical trails for lung cancer using cetuximab are underway (14) .
Most common of the rearrangements in human gliomas were genomic alterations leading to deletion of exon 2-7 in the EGFR mRNA (EGFRvIII), which causes an in-frame truncation of 801 bp in the extracellular domain of the molecule expressed in 24-67% of cases (15) (16) (17) (18) . This EGFRvIII mutation is highly correlated with EGFR amplification (19, 20) . Previous work has shown that 16% of NSCLC expressed EGFRvIII (21) , and another study showed that 39% of NSCLC had EGFRvIII mutation (22) . However, these results were confirmed by immunohistochemical analysis.
The standard for experimental detection of mutations is direct sequencing of DNA samples from the tissues. However, for known mutations, real-time polymerase chain detection followed by melting curve analysis, using hybridization probes, is highly sensitive, rapid and an efficient alternative approach to mutation detection (8, 23, 24) . To determine the EGFR mutation status in Japanese lung carcinoma for screening and diagnostic purpose, we wanted to develop a faster and easier method to detect EGFRvIII mutations. In this study, we investigated EGFRvIII mutation status by the real-time RT-PCR assay using LightCycler (24) mutation specific sensor and anchor probes. Among the screening sequencing for total EGFR gene, two EGFRvIII mutation patients were found (25) . These samples were used as a positive control for further study. The findings were compared to the clinicopathologic features of lung cancer.
Patients and methods
Patients. The study group included 252 lung cancer patients who had undergone surgery at the Department of Surgery II, Nagoya City University Medical School Hospital between 1997 and 2003. All tumor samples were immediately frozen and stored at -80˚C until assayed. These samples were sequenced for EGFR kinase domain by ABI PRISM 3100 analyzer (Applied Biosystems Japan Ltd., Tokyo, Japan) (7, 9) and analyzed by ABI PRISM Seq Scape version 2.1.1.
The clinical and pathological characteristics of the 252 lung cancer patients were: 132 cases at stage I, 38 at stage II, and 82 at stage III-IV. The mean age was 65.3 years (range, 42-88). Among the 252 lung cancer patients, 139 (55.1%) were diagnosed as adenocarcinoma, 87 (34.5%) were squamous cell carcinoma, 12 (4.8%) were adenosquamous cell carcinoma, and 6 (2.4%) were large cell carcinoma. Written informed consent was obtained from the patients, and the study was approved by the institutional ethics committee of the Nagoya City University Medical School.
PCR assays for EGFRvIII. Total RNA was extracted from lung cancer tissues and adjacent non-malignant lung tissues using Isogen kit (Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions. RNA concentration was determined by a spectrophotometer and adjusted to a concentration of 200 ng/ml. RNA (1 μg) was reverse transcribed by Superscript II enzyme (Gibco BRL, Gaithersburg, MD) with 0.5 μg oligo(dT) [12] [13] [14] [15] [16] (Amersham Pharmacia Biotech Inc. Piscataway, NJ). Initially, several cDNA samples were also sequenced and EGFRvIII mutations found (25) . The sets of cDNA were used as a positive and negative control for genotyping. DNA concentration was determined by spectrophotometer and adjusted to a concentration of 50 ng/ml. We then used 1 μl of each DNA for LightCycler analyses. To ensure the fidelity of cDNA transcription, all samples were subjected to PCR amplification with oligonucleotide primers specific for the constitutively expressed gene glyceraldehyde-3-phosphate dehydrogenase. The genotyping PCR reactions were performed using LightCycler DNA Master hybridization probe kit (Roche Molecular Biochemicals, Mannheim, Germany) in a 20-μl reaction volume. The primer sequences for EGFRvIII gene were: forward primer, 5-CAGTATTGATCGGGAG AG-3 and the reverse primer, 5-CATCTCATAGCTGT CGGC-3 (197 bp). For EGFRvIII genotyping, sensor (TGCGCTCTGCCCGGCGAGTGGG-fluorescein) and anchor (LC Red 640 TCTGGAGGAAAAGAAAGGTA ATTATGTGGTG-phosphate) probes were used.
EGFR DNA copy number. The EGFR gene copy number was analyzed by quantitative real-time PCR, performed on a PRISM 750 sequence detector (Applied Biosystems) by using a QunatiTect SYBR Green kit (Qiagen, Inc., Valencia, CA) (9) . We quantified each tumor DNA by comparing the target locus to the reference Line-1, repetitive element for which copy numbers per haploid genome are similar among all of the human normal and neoplastic cells. Quantification is based on standard curve from a serial dilution of human normal lung genomic DNA. The relative EGFR copy number level was normalized to normal human genomic DNA as calibrator. Copy number change of EGFR gene relative to the Line-1 and the calibrator were determined by using the formula (T EGFR /T Line-1 )/(C EGFR / C Line-1 ), where T EGFR and T Line-1 are quantity from tumor DNA by using target and Line-1. PCRs for each primer set were performed in at least triplicate, and means were reported. Conditions for quantitative PCR reaction were: one cycle of 50˚C for 2 min, one cycle of 95˚C for 15 min, 40 cycles of 95˚C for 15 sec, 56˚C for 30 sec, and 72˚C for 34 sec. At the end of the PCR reaction, samples were subjected to a melting analysis to confirm specificity of the amplicon. Primer sequences for EGFR gene used are: forward: CCACCAAATTAGCCTGGACA and reverse: CGCGACC TTAGGTATTCTG.
Statistical analysis. Statistical analyses were done using the Mann-Whitney U test for unpaired samples and Wilcoxon's Table I . Clinicopathological data of 252 lung cancer patients.
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N+, lymph node metastasis positive; Adeno, adenocarcinoma.
-------------------------------------------------
signed rank-test for paired samples. Linear relationships between variables were determined by means of simple linear regression. Correlation coefficients were determined by rank correlation using Spearman's test and ¯2 test. The analyses were done using the Stat-View software package (Abacus Concepts Inc. Berkeley, CA), and was considered significant at p-value <0.05.
Results

Sequence results for EGFR gene at kinase domain in lung cancer tissues.
The EGFR mutation status in kinase domain was reported (7) (8) (9) . From the 252 lung cancer patients, 60 had an activating mutation; 21 were male (35.0%) and 39 were female. Forty were non-smokers (66.7%) and 20 were smokers. Fifty-five patients had adenocarcinoma (91.7%), 3 had squamous cell carcinoma and 2 had adenosquamous cell carcinoma. Thus, EGFR mutation status at kinase domain was significantly correlated with gender, smoking status and the pathological subtypes (adenocarcinoma vs. others) of lung cancer (p<0.0001) ( Table I) .
Genotyping of EGFRvIII in lung cancer tissues.
For genotyping, the anchor probe was matched for EGFRvIII mutation. As shown in Fig. 1 , EGFRvIII mutation through exon 2-7 PCR products showed a single peak at 63˚C, whereas the wild-type showed no peak. From the 252 lung cancer patients, 8 had an EGFRvIII mutation (Table II) . Adjacent matchedlung tissues (7/8) were available and showed no peak from PCR assays, suggested that these EGFRvIII mutations were somatic. All were male and smokers. Brinkman index was significantly higher in EGFRvIII mutant (1627.5±824.1) than in non-EGFRvIII patients (736.3±680.4) (p=0.0001). Seven patients had squamous cell carcinoma and 1 had an adeno- carcinoma. Adenocarcinoma patients 0.7% (1/139) and squamous cell carcinoma patients 8.0% (7/87) had EGFRvIII mutations. Squamous cell carcinoma patients had significantly higher incidence of EGFRvIII mutations than adenocarcinoma patients (p=0.0114). EGFRvIII mutant patients did not have EGFR mutations at kinase domain. Thus, EGFRvIII mutation and EGFR mutation at kinase domain were exclusive.
Of the 252 NSCLC patients, 14 were treated with gefitinib after relapse of lung cancers. Nine EGFR kinase domain mutations were detected from these 14 lung cancer specimens. In 7 patients gefitinib therapy was effective; 6/7 gefitinib responder had EGFR kinase domain mutations. On the contrary, no EGFRvIII mutation was found in the 7 gefitinib responder patients.
Analysis of EGFR DNA copy number.
The EGFR gene copy number of 131 samples from lung cancer patients was analyzed by quantitative real-time PCR. Of 131 (8.4%) cases, 11 were found to have EGFR DNA amplifications (copy number >3). Of 8 (37.5%) EGFRvIII mutant patients, 3 had increased copy number. The FISH analyses for two EGFRvIII mutant patients with EGFR increased copy number, were published as supporting information (25) .
EGFR gene copy number was significantly higher in EGFRvIII samples (4.711±4.968) than in non-EGFRvIII samples (2.284±1.224) (p=0.0001).
Discussion
We obtained results that the incidence of EGFRvIII mutation was higher in patients with squamous cell than adenocarcinomas. Somatic EGFRvIII mutation existed exclusively with EGFR kinase domain mutations. Recent studies have shown that EGFR gene mutations at kinase domain are common in lung cancers from 'never smokers' and females with adenocarcinoma (7) (8) (9) (10) . Our analysis suggested that the population of somatic EGFRvIII mutations and the EGFR mutations at kinase domain in lung cancers was different. Increased copy number of EGFR gene was seen in EGFRvIII samples.
The development of immunotherapy strategies for NSCLC will be facilitated by the identification of tumor-specific targets. Although the EGFR is overexpressed in many cases of NSCLC, its wide distribution in normal tissue, such as liver and skin may limit its suitability as an immunotherapeutic agent. The anti-EGFR monoclonal antibody, cetuximab, has good clinical activity in ~10% of patients with metastatic colorectal cancer (13, 26) . The cetuximab treatment for NSCLC appears promising from preclinical data (14, 27) . However, the mutation status of the EGFR catalytic domain and its immediate downstream effectors PIK3CA, KRAS, and BRAF did not correlate with disease response to cetuximab (13) . Most colon cancer patients with objective response had an increased EGFR copy number (13) . Previous work has shown that the positive staining with the EGFRvIII antibody was highly correlated with EGFR amplification (18) . Thus, it would be of interest to determine whether sensitivity to EGFR antibody therapy emerges through EGFRvIII mutation. Mutations within the EGFR that are unique to malignancies may provide specific targets for immunotherapeutic intervention. The importance of EGFRvIII as a new anti-cancer therapeutic target was recently highlighted (28) (29) (30) . Monoclonal antibody 806 inhibited the tumor growth expressing EGFRvIII of amplified EGFR but not wild-type EGFR (30) .
Of the naturally occurring variant forms, EGFRvIII is the most common and is present in 50-60% of high grade gliomas, 70% of breast carcinomas, and 70% of ovarian neoplasms, but not in normal tissues (31) . Structurally, the EGFRvIII gene is missing 801 coding bases, spanning exons 2-7 of the wild-type gene (15) (16) (17) (18) (19) (20) (21) (22) 31) . Since our results showed fewer EGFRvIII mutation incidences than previous studies (21, 22) , some other EGFRvIII mutation phenotypes might exist.
Cappuzzo et al reported that high EGFR copy number identified by FISH, but not EGFR mutation at kinase domain, might be an effective molecular predictor for efficacy of gefitinib in NSCLC (32). Tsao et al reported that high copy number of EGFR, but not EGFR mutation at kinase domain, correlated with longer survival in erlotinib-treated NSCLC patients (33) , although, in the Japanese population, these data are controversial (34) . A recent study showed that EGFRvIII mutant tumors intermediate responded to gefitinib and erlotinib. EGFRvIII mutant cell lines or tumor strongly responded to HKI-272, another tyrosine kinase inhibitor. Thus, detection of EGFR mutations should be of clinical Table II . Clinicopathological data of 8 lung cancer patients with EGFRvIII. Gender  Age  Smoking status  Histology  Differentiation  EGFR kinase domain ---------------------------------------------------------------------------------------------------- M, male; F, female; SCC, squamous cell carcinoma; WT, wild-type.
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mutation -----------------------------------------------------------------------------------------------------
-- --------------------------------------------------------------------------------------------------- importance in predicting the sensitivity or resistance to molecular-target therapy for lung cancer, especially in squamous cell lung carcinomas.
